Genomic Health Innovations 

Luncheon/Webcast of June 6, 2013 at the Yale Club in New York

11:00 am to noon -  Networking
 noon to 1:00 pm -    Luncheon
1:00 pm - 2:00 pm - Presentation 

Abstract

Genomic Medicine Innovations are rapidly reaching the healthcare market place and changing the way how diseases are diagnosed and treated.  Advancements in our understanding of basic human biology, medicine, chemistry, instrumentation and technology to analyze big data sets are converging to redefine how diseases are diagnosed, managed and treated.   A series of entrepreneurial health and life science companies are developing solutions to help manage more valuable outcomes for patients, providers and payors alike.  

Panel

Piraye Yurttas Beim, PhD/Founder and Chief Executive Officer, Celmatix
Harry A. Glorikian, Managing Director, Strategy, Precision for Medicine
Mark Monane, Cheif Medical Officer, CardioDx
Paul Pospisil, PhD, Senior Client Partner at Korn/Ferry International
Nathan Tinker, PhD, Executive Director of the New York Biotechnology Association (NYBA)

STEM Education is Key to Restoring U.S. Global Competitiveness and Prosperity. Nowadays USA’s 15-year-olds rank 25th in math and 17th in science. CEOs cannot find enough STEM talent in USA which results in lost high paying JOBS. Please become a STEM supporter to advance the ACS scholars program, the National Chemistry Week for children K-12 to do hands-on experiments, mentoring of highly gifted students and programs that inspire STEM careers.  

Speakers Bios  

 Dr. Piraye Yurttas Beim, is the founder and CEO of Celmatix, a New York City based entrepreneurial company that is developing diagnostic tools to improve reproductive health outcomes for female infertility. By partnering with fertility clinics and other stakeholders, we are enabling better use of electronic medical data and discovering predictive genetic biomarkers that clarify idiopathic infertility and flag premature menopause risk. Our offerings will help physicians interpret data, clarify causes of treatment failure, and optimize treatment strategies to improve success rates.

 Dr. Beim is one of a handful of experts in the genetics of female fertility. Her postdoctoral work (Gurdon Institute, University of Cambridge, England) is in mammalian pre-implantation embryology and her doctoral work (Cornell University, Weill Medical College/Sloan Kettering Institute, NYC) focused on the molecular and genetic underpinnings of mammalian infertility. Dr. Beim holds a BA in Plan II Honors, an elite multidisciplinary honors program, and a BS in Biology from the University of Texas at Austin.

Mr. Harry A. Glorikian has been Managing Director of Strategy and Personalized Medicine at Precision for Medicine, Inc. since joining in December 2012. Mr. Glorikian has more than 20 years of experience in the health care and life science industries. He has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology, and biodefense. His unique understanding of technologies has shaped a sophisticated framework and proprietary analytic tools. Prior to Precision, Mr. Glorikian founded Scientia Advisors, LLC. and serves as its Managing Partner. He served as Principal and Management Consultant of TSG Partners. He held several senior management positions with Applera's Applied Biosystems, Signet Laboratories. He is Co-Founder of X-Cell Laboratories. He has been a Director of GeneNews Limited since May 2008. Mr. Glorikian serves on the advisory board of Draper Laboratories. Mr. Glorikian has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress, and other audiences worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, BioWorld Today, Los Angeles Times, Medical Device Daily, Science Magazine, and other media outlets. He is an avid inventor who has several patents in the U.S. and abroad. He  holds a Masters of Business Administration from Boston University, and a BA, General Biology from San Francisco State University.

Mark Monane is Chief Medical Officer at CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient.. Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on analyses of emerging biotechnology companies in the cardiovascular and cancer disease areas. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health. Before joining Medco, he was an assistant professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness. Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. in health policy from Harvard University, and an M.D. from NYU.

Paul Pospisil, Ph.D., is Senior Client Partner at Korn/Ferry International, where he recruits for positions such as chief executive officer, chief business officer, head of research and development and other key positions. With over fifteen years in the industry as a successful executive and investor, Mr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in new product development, business development, M&A, financings, strategy, company building, operational leadership and board functions from start-up, growth to mature biotechnology and biopharmaceutical companies. Prior to joining Korn/Ferry, Mr. Pospisil was a co-founder and managing partner of Aduro Capital LLC. Previously, he was a partner in life science investments at Atlas Venture and earlier was director, strategy leadership at Millennium Pharmaceuticals. Paul holds a Ph. D. in organic chemistry from Harvard University and a bachelor’s degree in biochemistry from NYU. 

Nathan Tinker, Ph.D., is Executive Director of the New York Biotechnology Association (NYBA), the statewide trade association representing New York¹s bioscience community. He serves as a spokesman and advocate for the state¹s industry. NYBA supports the development and growth of New York State's biotechnology industry, and serves its members and the biotechnology community by providing a network for information exchange, shared services, and collective action. He is a member of the Executive Pharmaceutical Advisory Board at Physicians Interactive. He participated in the Governor's task force on Diversifying the NY State Economy through Industry-Higher Education Partnerships. Previously, he was Executive Director at the Sabin Vaccine Institute and Founder and Executive Vice President at NanoBusiness Alliance. He holds a PhD from Fordham University, an M.A. from Georgetown University and has a degree in English from Gonzaga University.